Rose E. Sekulovich - Concepedia

Author

Rose E. Sekulovich

Arcturus Therapeutics (United States)ORCID

Also Known As

R E Sekulovich, R Sekulovich, R. E. Sekulovich, R. Sekulovich, ROSE E. SEKULOVICH, ROSE SEKULOVICH, Rose E. Sekulovich, Rose Sekulovich, Rose E. Sekulovich

Publications

Citations

H-Index

Concepts

All Affiliations

Arcturus Therapeutics (United States)University of Washington University of California, Irvine Singapore General Hospital Chiron (Norway)

About

Rose E. Sekulovich is an author at Arcturus Therapeutics (United States) specializing in medicine, virology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	828
2	Natural Sciences	4	4	329
3	Allergy	2	2	28
4	Public Health	1	1	21
5	Biochemistry	1	1	18

Rose E. Sekulovich

Publications

Citations

H-Index

Page 1

	Year	Citations
Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection Lawrence Corey, Andria Langenberg, Rhoda L. Ashley, JAMA	1999	483
A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant Robert F. Pass, Anne‐Marie Duliège, Suresh B. Boppana, The Journal of Infectious Diseases	1999	247
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes Stephen E. Straus, Barbara Savarese, Philip R. Krause, The Lancet VaccinationVaccine DevelopmentVaccine TargetImmunologyGenital Herpes	1994	206
The herpes simplex virus type 1 alpha protein ICP27 can act as a trans-repressor or a trans-activator in combination with ICP4 and ICP0 Rose E. Sekulovich, K Leary, R M Sandri-Goldin Journal of Virology Viral ReplicationViral PathogenesisImmunologyMolecular BiologyIcp27 Gene	1988	188
Immunotherapy of Recurrent Genital Herpes with Recombinant Herpes Simplex Virus Type 2 Glycoproteins D and B: Results of a Placebo‐Controlled Vaccine Trial Stephen E. Straus, Anna Wald, Rhonda G. Kost, The Journal of Infectious Diseases	1997	168
Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit Vaccine Sharon E. Frey, Christopher Harrison, Robert F. Pass, The Journal of Infectious Diseases	1999	106
Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens Michael Tigges, David M. Koelle, Karin Hartog, Journal of Virology Human Cd8+Viral PersistenceCd4+ CellsHuman RetrovirusImmunology	1992	101
The regions important for the activator and repressor functions of herpes simplex virus type 1 alpha protein ICP27 map to the C-terminal half of the molecule Mary Ann Hardwicke, P Vaughan, Rose E. Sekulovich, Journal of Virology Viral ReplicationImmunologyMolecular BiologyIcp27 GeneViral Structural Protein	1989	82
Limited Antibody‐Dependent Cellular Cytotoxicity Antibody Response Induced by a Herpes Simplex Virus Type 2 Subunit Vaccine Steve Kohl, Edwin D. Charlebois, Mavash Sigouroudinia, The Journal of Infectious Diseases VaccinationVaccine DevelopmentVaccine ResearchVaccine TargetImmunology	2000	67
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials Nhân Thị Hồ, Steven G. Hughes, Van Thanh Ta, Nature Communications	2024	67

Page 1